CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-08-24 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −50,822 | $29.48 | $1.5M | 7,807,196 |
| 2021-08-24 | GADICKE ANSBERT Director | Sale | −7,025 | $29.48 | $207K | 266,520 |
| 2021-08-24 | GADICKE ANSBERT Director | Sale | −50,882 | $29.48 | $1.5M | 7,807,196 |
| 2021-08-23 | Zawel Leigh See Remarks | Sale | −28,118 | $29.00 | $815K | 93,524 |
| 2021-08-23 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −53,359 | $29.11 | $1.6M | 7,858,018 |
| 2021-08-23 | GADICKE ANSBERT Director | Sale | −7,376 | $29.11 | $215K | 273,545 |
| 2021-08-23 | GADICKE ANSBERT Director | Sale | −53,359 | $29.11 | $1.6M | 7,858,018 |
| 2021-08-23 | Zawel Leigh See Remarks | Sale | −28,118 | $29.00 | $815K | 93,524 |
| 2021-08-18 | Michaelson Jennifer See Remarks | Option exercise | +4,000 | $4.30 | $17K | 26,911 |
| 2021-08-18 | Michaelson Jennifer See Remarks | Sale | −2,863 | $27.50 | $79K | 24,048 |
| 2021-08-18 | Michaelson Jennifer See Remarks | Sale | −1,137 | $28.07 | $32K | 22,911 |
| 2021-08-18 | Michaelson Jennifer See Remarks | Option exercise · Stock Option (Right to Buy) | −4,000 | 225,978 | ||
| 2021-08-18 | Michaelson Jennifer See Remarks | Option exercise | +4,000 | $4.30 | $17K | 26,911 |
| 2021-08-18 | Michaelson Jennifer See Remarks | Sale | −2,863 | $27.50 | $79K | 24,048 |
| 2021-08-18 | Michaelson Jennifer See Remarks | Sale | −1,137 | $28.07 | $32K | 22,911 |
| 2021-08-18 | Michaelson Jennifer See Remarks | Option exercise · Stock Option (Right to Buy) | −4,000 | 225,978 | ||
| 2021-08-11 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −2,510 | $29.05 | $73K | 7,911,377 |
| 2021-08-11 | GADICKE ANSBERT Director | Sale | −347 | $29.05 | $10K | 280,921 |
| 2021-08-11 | GADICKE ANSBERT Director | Sale | −2,510 | $29.05 | $73K | 7,911,377 |
| 2021-08-10 | Zawel Leigh See Remarks | Sale | −1,906 | $26.50 | $51K | 126,650 |
Page 19 of 23 · 446 trades